Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma
暂无分享,去创建一个
Y. Li | Ying Li | Liang Yu | Huiwu Li | Hui Li | Yike Li | Ling Liu | Yan Chen | Yibulayin Waresijiang
[1] Jianfei Shen,et al. miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. , 2019, Journal of thoracic disease.
[2] Q. Peng,et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma , 2018, Investigational New Drugs.
[3] Miao Deng,et al. Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[4] Y. Takeda,et al. Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer , 2018, Cancer science.
[5] J. Lagergren,et al. Global time trends in the incidence of esophageal squamous cell carcinoma , 2018, Clinical epidemiology.
[6] B. Groner,et al. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells , 2018, Archives of Toxicology.
[7] Tuan Leng Tay,et al. Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context‐Dependent Manner , 2018, Immunity.
[8] H. Kafil,et al. Deregulated expression of HDAC3 in colorectal cancer and its clinical significance. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[9] M. Christmann,et al. HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130 , 2018, Nature Communications.
[10] Meng Li,et al. Histone Deacetylase 1 Plays an Acetylation-Independent Role in Influenza A Virus Replication , 2017, Front. Immunol..
[11] Minghui Zhang,et al. Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5 , 2017, International journal of molecular medicine.
[12] F. Tirone,et al. HDAC1, HDAC4, and HDAC9 Bind to PC3/Tis21/Btg2 and Are Required for Its Inhibition of Cell Cycle Progression and Cyclin D1 Expression , 2017, Journal of cellular physiology.
[13] Lianhua Liu,et al. The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy , 2017, Oncotarget.
[14] Elizabeth E. Hull,et al. HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.
[15] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[16] Meng Zhuo,et al. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer , 2016, Oncotarget.
[17] Somy Yoon,et al. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases , 2016, Chonnam medical journal.
[18] D. Harrison,et al. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer , 2015, Oncotarget.
[19] E. Chiocca,et al. Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy , 2015, Oncolytic virotherapy.
[20] G. Sauter,et al. HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. , 2015, Experimental and molecular pathology.
[21] M. Boerries,et al. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine , 2015, Epigenetics.
[22] Furhawn A. Shah,et al. Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis , 2014, Oncology letters.
[23] G. Sica,et al. Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer , 2014, Cancer Prevention Research.
[24] Limei Liu,et al. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. , 2013, Cancer letters.
[25] Wei He,et al. HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. , 2013, Clinical and investigative medicine. Medecine clinique et experimentale.
[26] J. Zhao,et al. X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer , 2012, Radiation oncology.
[27] I. Rahman,et al. Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD. , 2012, American journal of physiology. Lung cellular and molecular physiology.
[28] Suk Woo Nam,et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins , 2012, Journal of cellular biochemistry.
[29] V. Beral,et al. Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy , 2011, Journal of the National Cancer Institute.
[30] R. Langer,et al. Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study , 2010, Journal of Clinical Pathology.
[31] T. Shiozawa,et al. Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin , 2010, International journal of cancer.
[32] R. Langer,et al. Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer , 2010, Annals of Surgical Oncology.
[33] S. Motoyama,et al. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung , 2010, Tumor Biology.
[34] H. Matsubara,et al. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. , 2009, Anticancer research.
[35] P. Barnes. Histone deacetylase-2 and airway disease , 2009, Therapeutic advances in respiratory disease.
[36] D. Saur,et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.
[37] O. Witt,et al. HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.
[38] W. Weichert,et al. Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.
[39] H. Matsubara,et al. Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer. , 2008, Anticancer research.
[40] Carsten Denkert,et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.
[41] J. Davie,et al. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[42] E. Seto,et al. Histone deacetylases and cancer , 2007, Oncogene.
[43] Hiroko Yamashita,et al. Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.
[44] M. Salto‐Tellez,et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.
[45] Y. Ikeda,et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. , 2003, Oncology reports.
[46] Yuka Kanno,et al. Interaction of Histone Acetylases and Deacetylases In Vivo , 2003, Molecular and Cellular Biology.
[47] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[48] J. Qin,et al. Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3 , 2000, The EMBO journal.
[49] S. Schreiber,et al. A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.
[50] N. Zhang,et al. HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells. , 2017, Oncology letters.
[51] V. Ganapathy,et al. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. , 2009, The Biochemical journal.